A business in context

GALT research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. DEF 14A · Proxy statement

    Report date 2026-12-03 · 0001140361-26-039379

  2. 8-K · Current report

    Report date 2026-08-14 · 0001140361-26-032946 · Items 2.02,9.01

  3. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001140361-26-032945

  4. 8-K · Current report

    Report date 2026-07-31 · 0001140361-26-031058 · Items 3.02,9.01

  5. 4 · Ownership change

    Report date 2026-07-31 · 0001133416-26-000065

  6. 4 · Ownership change

    Report date 2026-07-14 · 0001133416-26-000063

  7. 4 · Ownership change

    Report date 2026-06-26 · 0001133416-26-000061

  8. 4 · Ownership change

    Report date 2026-06-26 · 0001133416-26-000059

  9. 4 · Ownership change

    Report date 2026-06-23 · 0001133416-26-000057

  10. 8-K · Current report

    Report date 2026-06-23 · 0001140361-26-026031 · Items 7.01,9.01

  11. 4 · Ownership change

    Report date 2026-05-26 · 0001133416-26-000055

  12. 8-K · Current report

    Report date 2026-05-15 · 0001140361-26-021496 · Items 2.02,9.01

  13. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001140361-26-021495

  14. 8-K · Current report

    Report date 2026-03-31 · 0001140361-26-012158 · Items 2.02,9.01

  15. 10-K · Annual report

    Report date 2025-12-31 · 0001140361-26-012155

  16. 8-K · Current report

    Report date 2026-03-12 · 0001140361-26-009735 · Items 5.02,9.01

  17. 4 · Ownership change

    Report date 2026-03-12 · 0001133416-26-000053

  18. 4 · Ownership change

    Report date 2026-02-06 · 0001133416-26-000048

  19. 8-K · Current report

    Report date 2026-01-16 · 0001140361-26-001866 · Items 5.02

  20. 8-K · Current report

    Report date 2026-01-10 · 0001140361-26-000994 · Items 5.02

  21. 8-K · Current report

    Report date 2025-12-19 · 0001140361-25-046115 · Items 1.01,9.01

  22. 8-K · Current report

    Report date 2025-12-03 · 0001140361-25-044711 · Items 5.07

  23. 8-K · Current report

    Report date 2025-12-03 · 0001140361-25-044148 · Items 7.01,9.01

  24. 8-K · Current report

    Report date 2025-11-14 · 0001140361-25-042118 · Items 2.02,9.01

  25. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001140361-25-042116

  26. 8-K · Current report

    Report date 2025-11-10 · 0001140361-25-041275 · Items 7.01,9.01

  27. DEF 14A · Proxy statement

    Report date 2025-12-03 · 0001140361-25-038875

  28. 8-K · Current report

    Report date 2025-09-08 · 0001140361-25-034242 · Items 7.01,9.01

  29. 8-K · Current report

    Report date 2025-08-14 · 0001140361-25-031041 · Items 2.02,9.01

  30. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001140361-25-031039

  31. 8-K · Current report

    Report date 2025-07-08 · 0001140361-25-025295 · Items 1.01,5.02,9.01

  32. 8-K · Current report

    Report date 2025-06-16 · 0001140361-25-022574 · Items 7.01,9.01

  33. 8-K · Current report

    Report date 2025-05-15 · 0001140361-25-019151 · Items 2.02,9.01

  34. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001140361-25-019149

  35. 8-K · Current report

    Report date 2025-05-12 · 0001140361-25-018277 · Items 7.01,8.01,9.01

  36. 8-K · Current report

    Report date 2025-03-31 · 0001140361-25-011174 · Items 2.02,9.01

  37. 10-K · Annual report

    Report date 2024-12-31 · 0001140361-25-011169

  38. 8-K · Current report

    Report date 2025-03-05 · 0001140361-25-007063 · Items 7.01,9.01

  39. 8-K · Current report

    Report date 2025-02-18 · 0001140361-25-004971 · Items 8.01,9.01

  40. 8-K · Current report

    Report date 2025-01-23 · 0001140361-25-002125 · Items 5.07

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 1 transaction rows1SGrant / award: 0 transaction rows0AExercise / conversion: 6 transaction rows6MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

7 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-07-31
2026-08-04
Uihlein Richard EM · Exercise / conversion
Acquired
Common Stock2550932.04.05
2026-07-31
2026-08-04
Uihlein Richard EM · Exercise / conversion
Acquired
Common Stock31825235.03.0
2026-07-31
2026-08-04
Uihlein Richard EM · Exercise / conversion
Disposed
Line of Credit Convertible Notes
Derivative security
n/a95475705.0
2026-07-31
2026-08-04
Uihlein Richard EM · Exercise / conversion
Disposed
Line of Credit Convertible Notes
Derivative security
n/a10331275.0
2026-07-14
2026-07-16
Jamil KhurramS · Sale
Disposed
Common Stock16250.05.13
2026-07-14
2026-07-16
Jamil KhurramM · Exercise / conversion
Acquired
Common Stock16250.03.04
2026-07-14
2026-07-16
Jamil KhurramM · Exercise / conversion
Disposed
Stock option (right to buy)
Derivative security
16250.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001133416GALECTIN THERAPEUTICS INC

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • PRO PHARMACEUTICALS INC · former SEC name · 2001-09-07 to 2011-05-26

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

No USD annual revenue periods with complete CPI coverage are available. Non-USD statements are not converted with U.S. CPI.

Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

Explore the CPI history ↗